Meeting
2016 ASCO Annual Meeting
Phase I study of the PD-L1 inhibitor, durvalumab (MEDI4736; D) in combination with a PARP inhibitor, olaparib (O) or a VEGFR inhibitor, cediranib (C) in Women's cancers (NCT02484404).
Authors
Jung-min Lee
National Institutes of Health, Bethesda, MD
Jung-min Lee , Alexandra Dos Santos Zimmer , Stan Lipkowitz , Christina M. Annunziata , Tony Weishiu Ho , Victoria L. Chiou , Lori M. Minasian , Nicole D. Houston , Irene Ekwede , Elise C. Kohn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Immune Checkpoint Inhibitors
Clinical Trial Registration Number
NCT02484404
Citation
J Clin Oncol 34, 2016 (suppl; abstr 3015)
DOI
10.1200/JCO.2016.34.15_suppl.3015
Abstract #
3015
Poster Bd #
337
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A phase 1 study optimizing the dosing of olaparib tablet formulation combined with cediranib in recurrent ovarian cancer.
First Author: Joyce Liu
First Author: B.J. Rimel
Poster
2023 ASCO Annual Meeting
A randomized trial of olaparib, durvalumab, and cancer vaccine, UV1, as maintenance therapy in patients with BRCAwt with recurrent ovarian cancer: ENGOT-OV56/NSGO-CTU-DOVACC trial.
First Author: Mansoor Raza Mirza
Poster
2023 ASCO Annual Meeting
A phase II study of olaparib and durvalumab in patients with IDH-mutated cholangiocarcinoma.
First Author: Erica S. Tsang